Achieve Life Sciences, Inc. Aktie News
4,74 $
0,96 %
gestern
Nasdaq,
3. Mai, 22:00 Uhr
tracken
Achieve Life Sciences, Inc. Aktie News
Neutral
GlobeNewsWire
●
9 Tage alt
SEATTLE and VANCOUVER, British Columbia, April 25, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced it will report its first quarter 2024 financial results and provide an update on the cytisinicline deve...
Positiv
Seeking Alpha
●
30 Tage alt
Achieve Life Sciences is working to commercialize the smoking cessation drug Cytisinicline, which has shown promising results in clinical trials. The drug has a superior safety profile compared to existing treatment options and has the potential to address a large market. The company is expected to be sold to a larger entity in 2025, with potential returns of 4-9x for investors.
Neutral
Seeking Alpha
●
etwa ein Monat alt
Achieve Life Sciences, Inc. (ACHV) Q4 2023 Earnings Call Transcript
Neutral
GlobeNewsWire
●
etwa ein Monat alt
Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024 Company to host conference call at 4:30 PM EDT today, Thursday, March 28, 2024
Neutral
GlobeNewsWire
●
etwa 2 Monate alt
SEATTLE and VANCOUVER, British Columbia, March 06, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Achieve management will be participating in the following upcoming investor conferences.
Neutral
GlobeNewsWire
●
2 Monate alt
Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025 Open-label exposure trial expected to initiate in Q2'24 with NDA filing anticipated in 1H 2025
Neutral
GlobeNewsWire
●
2 Monate alt
$60 million financing upfront with up to an additional $64.2 million tied to exercise of milestone-driven warrants
Negativ
InvestorPlace
●
5 Monate alt
Achieve Life Sciences (NASDAQ: ACHV ) stock is dropping on Tuesday after the company provided an update on its New Drug Application (NDA) for cytisinicline. A meeting with the Food and Drug Administration (FDA) saw the agency request additional data concerning cytisinicline before it will approve its NDA.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
